Have to agree that it wasnt, by far, the best deal, but I guess when your backs to the wall and bills need to be paid, you become hostage to fortune.
On the other hand a credible partnership could necessitate an improved debt situation.
At least they are now clear of debt and hopefully a more attractive potential long term partner. Guess we won't have to wait too long to find out.
Anyway back to Reneuron.
Incidentally, does anyone know if we were required to sign anything associated with the consolidation. Personally I've had no paperwork....all my shares are now paperless. Does anyone know if any action was necessary?
Tiny stem cell companies close in on major heart disease goal
NEW YORK (Reuters) - The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011.
But two small companies, Athersys Inc and Mesoblast Ltd, are beginning final stage trials in hundreds of patients that they - along with loyal investors - say could change the course of devastating stroke and heart failure.
Both have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues.
Cleveland-based Athersys, with a market value of about $200 million, demonstrated evidence in a midstage trial that its therapy may be able to expand the emergency treatment window for major strokes to up to 36 hours, compared with about four hours with current drugs, potentially allowing many more patients to avoid crippling disabilities.
Australias Mesoblast, with a market value of about $500 million, is attempting to alter advanced heart failure, a leading cause of hospitalizations and deaths and an enormous cost burden.
They are among the farthest along in the stem cell industry at a time when Wall Street investors have focused on potentially big payoffs from immune-system based cancer therapies and rare disease treatments.
Perception of the field has also been hurt by unscrupulous actors selling unapproved, possibly unsterile cell therapies for everything from cancer to lung disease and ALS, prompting a U.S. crackdown this past summer.
The market tends to test these companies sometimes to the brink, said Tom Dobell, who manages a fund for U.K.-based M&G Investment Management that specializes in supporting promising companies during difficult periods. Were comfortable that the progress thats going on is going to be worth it.
M&G is a long-time holder of Mesoblast, with about a 15 percent stake, and Athersys, with about 4 percent.
Athersyss experimental Multistem treatment was one of the first companies to be designated by the U.S. Food and Drug Administration as a promising cell-based therapy with potential to address unmet needs for serious or life threatening conditions, potentially easing the approval process.
FDA Commissioner Scott Gottlieb said in a recent interview the agency is seeking an approval pathway for legitimate stem cell therapies thats not overly burdensome.
The regenerative medicine space has been a tough road clinically and Athersys is one of the bright, shining stars, said Steven Martin, managing member of Chicago-based Aspire Capital and a long-time holder of Athersys shares.
REDUCING THE RISKS
Athersys believes Multistem - 1.2 billion cells delivered via simple intravenous drip - dampens the immune systems hyper-inflammatory reaction to signals that the brain is under attack during stroke, and promotes healing.
The bodys reaction to stroke may also severely deplete the immune system, leading to later complications beyond paralysis or speech impairment. In the Phase II trial, Multistem patients had significantly fewer incidents of pneumonia, acute pulmonary distress and other serious complications.
That trial, attempting to extend the treatment window to 48 hours, failed. But researchers were encouraged by patients treated up to 36 hours post stroke.
Its reason to be cautiously optimistic, said Dr. Ken Uchino, a leading Multistem investigator from Cleveland Clinic.
The company plans to begin a 300-patient Phase III study of Multistem in early 2018, aiming for U.S. and European approval after regulators agreed to protocols for one pivotal trial.
This reinforces and cements an efficient path forward for us, Athersys Chief Executive Gil Van Bokkelen said. A separate 220-patient Multiste
Hi Mol....thanks for info. I'm pleased that we all have a meeting of minds (agreed to debate Michael Hunt further).
I cannot understand why Neil Woodford still praises the company....perhaps he gets the updates we don't.
Anyway, enough venting of my frustration. Hopefully someone at Reneuron reads our posts and understands our frustration. Hopefully things will change for the better as I'm currently between a rock and a hard point, so just have to grin and bare the ongoing torture.
Just pleased I diverted some cash to Valirx...a company with better communicative skills, albeit financial expertise yet to be tested.
John Berriman 1,043,476 1,043,476
Olav Hellebø 669,422 322,778
Michael Hunt 2,008,471 1,758,471
Simon Cartmell OBE 787,500 787,500
Dr Tim Corn 200,000 200,000
Professor Sir Chris Evans OBE 24,010,525 24,010,525
Dr Paul Harper 451,709 451,709
Dr Mike Owen
we, as you know, are going down a different route to treat same
mind..... if successful and ahead of jcyte?
the lack though of regular updates by our company on website (even 080118 presentation ) - ie doesn't need an rns - nevermind breaking aim rules re major shareholders is a concern
though not as much as executive directors lack of share purchases on open market - which grizzlyb has again noted here - but a continuing theme over too many years now by, not only him, but numerous other posters and of course their options and salaries - really don't know why CE and remuneration board allows such a travesty
though i'm nowhere near down as much as said Sir CE at moment!
Woodford Patient update
ReNeuron received regulatory approval to start a phase IIb clinical study in the US for its CTX cell therapy for patients suffering from stroke disability. This is a great example of the patience that is required to achieve successful outcomes in this area of investing the CTX cell therapy technology has already been in its development phase for almost ten years.
Although this particular study is expected to read out in late 2019 and further pivotal trials are likely to be required before the company can progress towards market approval, the commercial opportunity ahead for ReNeurons innovative pipeline of assets is, in our view, substantial.
ReNeuron, thus far, is doing everything that we hoped it would in terms of operational development. The long-term potential here is undeniable but the short-term interest from the stock market remains almost imperceptible. In an increasingly short-term world, businesses like ReNeuron are exactly the sort of investment opportunity that the Patient Capital Trust was set-up to support, nurture and, ultimately, benefit from as they fulfil their commercial potential. As we have consistently said, not all will fulfil that potential, but the rewards for those that do succeed will be substantial.
makes no difference if u buy now or after consolidation.it will be worth the same
I remember gulf keystone went from £4 to 1p then consolidated (100-1) after a few weeks traded at 85p
just depends if you think it is going lower
I agree. my experience with share consolidations has always been a bad one. simply a higher starting price from which to begin the fall to oblivion. I hope I'm wrong but I don't think is a good move for us at all.
Agreed AI. I'd give Olav Helebo 0/10 for PR as far as PI's are concerned.
I guess we long-suffering small fry are too low down the pecking order to be of interest to him. No reply to emails/calls. I have had some luck with their PR guys but all you get is the party line...share is too lowly valued....can not understand why...etc etc.
I'm over £150k down and feeling very ignored.
At least Micheal Hunt delivered grant and involved himself with the politicians and scientific leaders.....as far as Olav is concerned, I'm still at a loss to know what he actually does. Clearly not leadership!
I feel for you and the other share holders. I did have a small dip here but sold out on news of consolidation. Generally this is bad news.
What everyone would prefer is for the management to take more responsibility and through their hard work, PR and better communication increase the share price rather than resorting to artificial means..
This is unbelievable......Helebo has to go unless he delivers, added value, by the share consolidation date!
As it stands right now I have 0% confidence in his ability to do so.
Funny these days, (in a disgusting way, that is), CEO's get rewarded for failure and the foot soldiers (in this case the boffins) get paid a pittance.
Hi OMG and thanks for the posts.
It is pleasing to read positive posts and I do hope the sp soon reflects the renewed hope.
I'm just annoyed the sp has been allowed to drop so low ...Mainly down to lack of investor interest, poor marketing and little director investment support.
I still hold a few million shares and welcome sustained recovery.
As far as Helebo is concerned.....he runs the show and his performance must be measured via share value....enough said. Thanks again for info and fingers crossed. Freddie
It's so disappointing Prospero.
Such a disaster it has to be self-inflicted......all the signs have been around for 2 years and each time the opportunity to capitalize on news presented itself the CEO allowed it to land a damp squid.
Every time......consistently....I despair....someone needs to fall on their sword and it's not the pr guys......its Helebo....he is the CEO and fully accountable for this mess.
If I was Woodford....I'd hang him out to dry.
I kept telling myself a deal was just around the corner....now what chance have we got to negotiate a decent deal when finances will soon place us on the back foot.
Why hasn't the manufacturing facility been licensed yet.....o'hhhh I forgot 'they have plenty of money to fund two third parties to manufacture for them'.
What happened to CLI.....results have probably been filed away.
What happening with the Aussie/NZ collaboration?
It's a joke.......a travesty.....someone has to pay....Helebo!!!!!!
Why aren't we bringing in revenue from exosomes....
What are the directors doing....one by one!!!
How are the RP trials going...surely there must be evidence of efficacy or not!!!
I'm running out of steam....just too frustrated!!!!!
Ref my last post... I should have written....ceased investing further...as I still hold significant Reneuron stock and all at a massive loss.
Also Happy new year to you Si. Let's hope it's a good one for bios generally. Best wishes. Fredo
PS. ...may hear from you on the val site, if not Reneuron?
Hi Simon. Good to hear from you. I'm so please I ceased investing in Reneuron and focused on Valirx. What a difference in management approach to investor relations.
My guess is that Reneuron scientists are steaming along in the laboratory and hospital wards while Olav is sipping coffee and chatting socially in his nice new office. I'm so disappointed with the top management team. Someone's got to slice through the fat with a sharp scalpel and then let the market know what they have done and why.....the why must restore investor confidence prior to the next fund raising initiative.
new year, same ol' sh...
Hope all and one are good , besides this and that with Rene.
Was looking to get back in but after reading the last page of posts I might take my next one on the list and go with V..
I have kept half an eye on what's going on, but TBH, I have kinda been way out of it for the last six months the have not been interested in any stocks.
Anyhoo, new year, new start and all that stuff. Miss the banter though.
Rene's share consolidation and the lack of JVs to support the pipeline suggests the company is positioning itself for a cash call in say 12 months time.
How can Rene ask shareholders for more cash without Board changes when they have: missed trial dates, the CEO , from memory, was appointed for his JV expertise and has not agreed one so far? Overall if Rene wants more cash then a few directors need to be sacked and new proven directors appointed - ones that deliver for shareholders by creating value not delays or pleas for more cash/time.
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.